Viela Bio, Inc. VIE
We take great care to ensure that the data presented and summarized in this overview for Viela Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in VIE
Top Purchases
Top Sells
About VIE
Insider Transactions at VIE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2021
|
Astrazeneca PLC > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
14,650,334
-100.0%
|
$776,467,702
$53.0 P/Share
|
|
Mar 13
2021
|
Yanling Cao Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
8,322,353
-100.0%
|
$441,084,709
$53.0 P/Share
|
|
Mar 13
2021
|
Zhengbin Yao Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
200,000
-100.0%
|
$10,600,000
$53.0 P/Share
|
|
Mar 13
2021
|
Zhengbin Yao Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
270,219
-100.0%
|
$14,321,607
$53.0 P/Share
|
|
Mar 13
2021
|
William Ragatz Senior VP, Head of Commercial |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,250
-100.0%
|
$861,250
$53.0 P/Share
|
|
Mar 13
2021
|
Jorn Drappa Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
202,661
-100.0%
|
$10,741,033
$53.0 P/Share
|
|
Mar 13
2021
|
Mitchell Chan Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
37,500
-100.0%
|
$1,987,500
$53.0 P/Share
|
|
Mar 13
2021
|
Boundless Meadow LTD > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
300,000
-100.0%
|
$15,900,000
$53.0 P/Share
|
|
Mar 13
2021
|
Boundless Meadow LTD > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
8,322,353
-100.0%
|
$441,084,709
$53.0 P/Share
|
|
Mar 13
2021
|
Edward Hu Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
4,161,177
-100.0%
|
$220,542,381
$53.0 P/Share
|
|
Mar 13
2021
|
Andreas Wicki Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,750,000
-100.0%
|
$92,750,000
$53.0 P/Share
|
|
Nov 18
2020
|
Aaron Ren Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.73%
|
$4,000
$2.84 P/Share
|
|
Oct 07
2019
|
Astrazeneca PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
425,000
+2.82%
|
$8,075,000
$19.0 P/Share
|
|
Oct 07
2019
|
Astrazeneca PLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
14,225,324
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders